Drug Trial Radar · NCT02212886
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Oct 2014
Primary completion
May 2017
Study completion Nov 20, 2024
Sponsor
- Lead sponsor
- Mapi Pharma Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* This is a phase IIa study in which GA Depot 80 or 40mg is administered as an IM injection to subjects with RRMS at 4 week intervals for 52 weeks of treatment. * The purpose of the study is to assess safety, tolerability, and efficacy of a monthly long-acting IM injection of 80 or 40mg GA Depot in subjects with RRMS. The study will include subjects switching from daily or thrice weekly administration of 20 mg or 40mg respectively of glatiramer acetate (GA, i.e., Copaxone®) injection
Conditions
- Multiple Sclerosis
Interventions
GA Depot 80 mgDrug
Recruitment completed
GA Depot 40 mgDrug
Recruitment completed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety / Adverse eventsTime frame: During the study
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Barzilai Medical Center
Ashkelon, Israel
Rambam Medical Center
Haifa, Israel
TASMC
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.